血脂康预处理对心肌缺血再灌注大鼠炎症因子影响

目的观察血脂康预处理对急性心肌缺血再灌注损伤大鼠炎症因子的影响,探讨其可能的作用机制。方法健康SD大鼠32只,随机分为空白组、假手术组、缺血再灌注组和血脂康预处理组,各8只。血脂康预处理组每天灌胃给予血脂康胶囊0.09 g/kg,其余各组给予等量生理盐水,连续7 d。缺血再灌注组和血脂康预处理组大鼠均开胸并结扎冠状动脉前降支30 min,然后再通60 min;假手术组只开胸不结扎冠状动脉,空白组不做任何处理。采集大鼠腹主动脉血,分离血清,检测白细胞介素(IL)-1βI、L-4I、L-8、肿瘤坏死因子(TNF-α)、肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTNI)含量,并处死动物取出心脏,计算心肌梗死面积。结果缺血再灌注组IL-1β、IL-4I、L-8、TNF-α、CK-MB和cTNI血清含量均明显高于空白组和假手术组(F=48.72~351.07,q=0.25~41.65,P<0.01);而血脂康预处理组上述指标除IL-4外均低于缺血再灌注损伤组(q=0.35~32.65,P<0.05),且血脂康预处理组大鼠心肌梗死面积小于缺血再灌注损伤组(F=231.26,q=17.21,P<0.05)。结论血脂康能抑制促炎因子IL-1βI、L-8、TNF-α的生成,并增加抗炎因子IL-4生成,减轻心肌缺血再灌注损伤,对缺血再灌注损伤具有明显的保护作用。

EFFECT OF XUEZHIKANG PRETREATMENT ON INFLAMMATORY FACTOR OF MYOCARDIAL ISCHEMIA-REPERFUSION INJURY IN RATS

Objective To observe the effects of Xuezhikang capsules on inflammatory factor of myocardial ischemia-reperfusion injury(MIRI) in rats and explore its possible mechanism of action. Methods Thirty-two SD rats were evenly randomized to four groups: blank group,sham-operation group,MIRI group and Xuezhikang pretreatment group.The rats in Xuezhikang group were treated with Xuezhikang(0.09 g·kg-1·d-1,gastric gavage) and other groups were treated with the same amount of saline,for 7 days.Those in MIRI and Xuezhikang pretreatment groups underwent a thoracotomy and the left anterior descending branch of coronary artery was ligated for 30 minutes and then recanalized for 60 minutes;those in sham-operation group received only thoracotomy with no ligation of coronary artery;no any management was done for those in the blank group.Blood samples were extracted from the abdominal aorta,and the serum separated.The interleukin-1β(IL-1β),IL-4,IL-8,tumor necrosis factor alpha(TNF-α),creatine kinase-MB(CK-MB),and troponinI were detected.The area of myocardial infarction(MI) was calculated. Results In MIRI group,the serum levels of IL-1β,IL-4,IL-8,TNF-α,CK-MB,and cTNI were significantly higher than those of normal group and sham-operation group(F=48.72-351.07,q=0.25-41.65,P<0.01),while the above parameters in the pretreatment group were lower than those of MIRI group,except IL-4(F=48.72-351,q=0.35-32.65,P<0.05).The area of MI in Xuezhikang pretreatment group was smaller than those in the MIRI(F=231.26,q=17.21,P<0.05). ConclusionXuezhikang can inhibit the production of proinflammatory factors,such as IL-1β,IL-8 and TNF-α,and increase anti-inflammatory IL-4,thus lessening ischemia-reperfusion inflammatory reaction and injury.